Cite
HARVARD Citation
Ray, K. et al. (n.d.). Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry. European heart journal. p. . [Online].